IP Library Granted Patent US 11,154,493
Granted Patent B2
US 11,154,493 · App. 16/078,925 · Granted Oct 26, 2021

Mitigating adverse effects of sunlight with ingredients obtained from living plants

Inventors: Olga Dueva-Koganov (White Plains, NY); Artyom Duev (White Plains, NY); Li Zhang (Princeton, NJ); Karine Cucumel (Opio, FR); Gilles Oberto (Valbonne, FR)
Assignee: ISP INVESTMENTS LLC
A61K8/9789A61Q19/08A61K2800/805A61K2800/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,154,493
App. No.
16/078,925
Granted
Oct 26, 2021
Kind
B2
Abstract

Disclosed herein are methods of improving skin appearance associated with skin aging. The method comprises the step of applying an anti-aging bioactive composition to a skin surface having at least one sign of aging. The anti-aging bioactive composition is applied for a period of time sufficient to improve the appearance of the at least one sign of aging. In one embodiment, the anti-aging bioactive composition comprises an effective amount of a Nelumbo nucifera (Sacred Lotus) serum fraction. In another embodiment, the anti-aging bioactive composition comprises an effective amount of a Chamomilla recutita (German Chamomile) Flower serum fraction. In other embodiments, the anti-aging bioactive composition can further include a dermatologically acceptable carrier.

Claims (9)

1. A method of improving skin appearance associated with skin aging by mitigating the adverse effects of full spectrum sunlight exposure on skin cells, said method comprising the step of topically applying an anti-aging bioactive composition to a skin surface

wherein said bioactive composition consists of i) a dermatologically acceptable carrier and ii) an effective amount of Nelumbo nucifera (Sacred Lotus) stabilized serum fraction,

wherein said Nelumbo nucifera serum fraction is isolated using a fractionation process comprising subjecting plant cell juice derived from fresh plant biomass of the fresh (living) whole plants of Nelumbo nucifera to an electromagnetic field at a frequency of greater than 2.45 GHz for a time effective to destabilize the plant cell juice yielding a coagulated cell juice mixture comprising a coagulated membrane fraction, and separating said coagulated membrane fraction from said coagulated cell juice mixture in order to yield a bioactive fraction comprising a cytoplasm/cytosole fraction that is substantially-free from said membrane fraction, followed by additional treatments enabling to separate cytoplasm fraction from cytosole fraction, and mixing the cytosole fraction with stabilizing agents to yield a Nelumbo nucifera stabilized serum fraction,

wherein said Nelumbo nucifera stabilized serum fraction has a dry matter ranging from between 6.59-6.78% w/w, a total soluble sugars ranging from between 2.29-2.54% w/w and a total phenolic compound ranging from 1.33-1.58% w/w; and

wherein said bioactive composition has properties on the skin selected from the group consisting of: increasing the expression of hyaluronic acid, filaggrin and AQP3 proteins, improving hydration, improving skin recovery after SDS stress, increasing the expression of collagen I, increasing the expression of filaggrin, improving organization of elastin fibers and decreasing melanin content,

wherein the said bioactive composition has a synergistic combination of properties selected from the group consisting of the following: (i) beneficial spectral absorbance characteristics in UVA-UVB area; (ii) high UVA:UVB absorbance ratios in conjunction with broad UVA and UVB spectral absorption photostability demonstrated after full spectrum simulated sun exposures; (iii) increased attenuation in UVA1 area and simultaneous increase in UVA/UVB ratio as radiation dose is increased; (iv) potent biological activities (properties) demonstrated in in vitro cell culture based ELISA (Enzyme-Linked ImmunoSorbent Assays) which measure the amount of cytokines (IL-6), chemokines (IL-8) and prostaglandins (PGE 2 ) in response to full spectrum simulated sun exposure and relevant enzymatic models which measure the inhibition of elastase and MMP3 (Matrix Metalloproteinase-3) (v) maintenance of more than 95% of initial (pre-irradiation) DPPH (2,2-Diphenyl-1-Picrylhydrazyl) quenching capacities after 4 MED exposure delivered by full spectrum simulated sunlight; (vi) multifunctional activities that work together to mitigate various adverse effects of full spectrum sunlight exposure on skin cells.

2. The method of claim 1 , wherein the bioactive composition comprises, by weight of the total composition, from 0.001% to 99% of said Nelumbo nucifera (Sacred Lotus) serum fraction.

3. The method of claim 1 , wherein the said bioactive composition has multifunctional activities that work synergistically to mitigate adverse effects of full spectrum sunlight exposure on skin cells.

4. The method of claim 1 , wherein the skin surface is selected from the group consisting of a body skin surface and a facial skin surface.

Assignments (2)
CHANGE OF NAME Recorded Aug 22, 2018
From: ISP INVESTMENTS INC.
To: ISP INVESTMENTS LLC
Reel/Frame 046910/0505 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2018
From: DUEVA-KOGANOV, OLGA; DUEV, ARTYOM; ZHANG, LI; CUCUMEL, KARINE
To: ISP INVESTMENTS INC.
Reel/Frame 046665/0190 →
Continuity (2)
Provisional Application 62299614 · Feb 25, 2016
Related Publication 20190282491A1 · Sep 19, 2019